Fibrocell Science Inc. wants to use $45 million from a private placement to reach more customers with LaViv (azficel-T), the personalized wrinkle therapy that harvests a sample of the patient's own cells by way of a skin-punch behind the ear, expands their collagen-making fibroblasts in the laboratory, and returns them by injection to nasolabial folds.